Table 6.

Comparison of OPA results in special populations after pneumococcal vaccination

Study		Feikin et al. [53]						Kumar et al. [56]		Dransfield et al. [59]
Target population		HIV-infected subjects with CD4 counts ≥200 cells/μl						Renal transplant recipients		COPD patients
Vaccine schedule (dosage)		PCV7 (0.5 ml)-PCV7 (0.5 ml) with 8 week interval		PCV7 (0.5 ml)-PPV23 (0.5 ml) with 8 week interval		Placebo-PPV23 (0.5 ml) with 8 week interval		PPV23 (0.5 ml)	PCV7 (0.5 ml)	PPV23 (0.5 ml)	PCV7 (1.0 ml)
Sample collection schedule		8 weeks post 1st vaccine	8 weeks post 2nd vaccine	8 weeks post 1st vaccine	8 weeks post 2nd vaccine	8 weeks post 1st vaccine	8 weeks post 2nd vaccine	8 weeks post vaccine	8 weeks post vaccine	1 year post vaccine	1 year post vaccine
OPA Titer by Serotype	4	40 (23–70)	46 (29–73)	20 (11–39)	16 (9–28)	15 (9–26)	18 (11–31)	173 (32–1,024)	208 (32–2,048)	62	268
	6B	116 (67–204)	169 (94–305)	48 (23–100)	57 (26–124)	45 (25–83)	49 (27–91)	199 (32–4,096)	294 (32–4,096)	229	476
	9V	39 (22–67)	46 (32–67)	24 (12–47)	23 (12–43)	17 (11–28)	20 (12–36)	79 (4–1,024)	83 (4–8,192)	142	444
	14	61 (37–101)	64 (37–112)	61 (23–161)	50 (24–105)	45 (18–117)	83 (35–198)	203 (4–2,048)	239 (4–4,096)	839	1,801
	18C	-	-	-	-	-	-	86 (4–2,048)	119 (4–2,048)	284	665
	19F	-	-	-	-	-	-	111 (16–1,024)	147 (8–2,048)	116	87
	23F	40 (25–66)	39 (22–69)	20 (10–39)	19 (11–34)	18 (13–25)	19 (14–27)	29 (4–512)	64 (4–2,048)	48	407

Note. Results are expressed as: Mean (95% CI) for Feikin et al; Mean (Range) for Kumar et al; and Mean for Dransfield et al.

OPA, opsonophagocytosis assay; GMC, geometric mean concentration; GMT, geometric mean titer (calculated from the reciprocal of the individual titers); CI, confidence interval; -, not reported